462 related articles for article (PubMed ID: 16321512)
21. Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts.
Sahara T; Itoh K; Debari K; Sasaki T
Anat Rec A Discov Mol Cell Evol Biol; 2003 Feb; 270(2):152-61. PubMed ID: 12524690
[TBL] [Abstract][Full Text] [Related]
22. The effect of molecules in mother-of-pearl on the decrease in bone resorption through the inhibition of osteoclast cathepsin K.
Duplat D; Gallet M; Berland S; Marie A; Dubost L; Rousseau M; Kamel S; Milet C; Brazier M; Lopez E; Bédouet L
Biomaterials; 2007 Nov; 28(32):4769-78. PubMed ID: 17686515
[TBL] [Abstract][Full Text] [Related]
23. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
[TBL] [Abstract][Full Text] [Related]
24. Localisation and activity of cathepsins K and B in equine osteoclasts.
Gray AW; Davies ME; Jeffcott LB
Res Vet Sci; 2002 Apr; 72(2):95-103. PubMed ID: 12027589
[TBL] [Abstract][Full Text] [Related]
25. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
Fuller K; Lindstrom E; Edlund M; Henderson I; Grabowska U; Szewczyk KA; Moss R; Samuelsson B; Chambers TJ
Bone; 2010 May; 46(5):1400-7. PubMed ID: 20097319
[TBL] [Abstract][Full Text] [Related]
26. Comparison in localization between cystatin C and cathepsin K in osteoclasts and other cells in mouse tibia epiphysis by immunolight and immunoelectron microscopy.
Yamaza T; Tsuji Y; Goto T; Kido MA; Nishijima K; Moroi R; Akamine A; Tanaka T
Bone; 2001 Jul; 29(1):42-53. PubMed ID: 11472890
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activators are involved in the degradation of bone by osteoclasts.
Everts V; Daci E; Tigchelaar-Gutter W; Hoeben KA; Torrekens S; Carmeliet G; Beertsen W
Bone; 2008 Nov; 43(5):915-20. PubMed ID: 18691680
[TBL] [Abstract][Full Text] [Related]
28. Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Ainola M; Valleala H; Nykänen P; Risteli J; Hanemaaijer R; Konttinen YT
Arthritis Rheum; 2008 Nov; 58(11):3394-401. PubMed ID: 18975331
[TBL] [Abstract][Full Text] [Related]
29. Cathepsin K, osteoclastic resorption, and osteoporosis therapy.
Zaidi M; Troen B; Moonga BS; Abe E
J Bone Miner Res; 2001 Oct; 16(10):1747-9. PubMed ID: 11585336
[No Abstract] [Full Text] [Related]
30. Development and characterization of a human in vitro resorption assay: demonstration of utility using novel antiresorptive agents.
James IE; Lark MW; Zembryki D; Lee-Rykaczewski EV; Hwang SM; Tomaszek TA; Belfiore P; Gowen M
J Bone Miner Res; 1999 Sep; 14(9):1562-9. PubMed ID: 10469285
[TBL] [Abstract][Full Text] [Related]
31. Grafting of features of cystatins C or B into the N-terminal region or second binding loop of cystatin A (stefin A) substantially enhances inhibition of cysteine proteinases.
Pavlova A; Björk I
Biochemistry; 2003 Sep; 42(38):11326-33. PubMed ID: 14503883
[TBL] [Abstract][Full Text] [Related]
32. Importance of the second binding loop and the C-terminal end of cystatin B (stefin B) for inhibition of cysteine proteinases.
Pol E; Björk I
Biochemistry; 1999 Aug; 38(32):10519-26. PubMed ID: 10441148
[TBL] [Abstract][Full Text] [Related]
33. Cystatin C in milk basic protein (MBP) and its inhibitory effect on bone resorption in vitro.
Matsuoka Y; Serizawa A; Yoshioka T; Yamamura J; Morita Y; Kawakami H; Toba Y; Takada Y; Kumegawa M
Biosci Biotechnol Biochem; 2002 Dec; 66(12):2531-6. PubMed ID: 12596844
[TBL] [Abstract][Full Text] [Related]
34. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of bone resorption by selective inactivators of cysteine proteinases.
Hill PA; Buttle DJ; Jones SJ; Boyde A; Murata M; Reynolds JJ; Meikle MC
J Cell Biochem; 1994 Sep; 56(1):118-30. PubMed ID: 7806585
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities.
Delaissé JM; Andersen TL; Engsig MT; Henriksen K; Troen T; Blavier L
Microsc Res Tech; 2003 Aug; 61(6):504-13. PubMed ID: 12879418
[TBL] [Abstract][Full Text] [Related]
37. Optimized transfection of diced siRNA into mature primary human osteoclasts: inhibition of cathepsin K mediated bone resorption by siRNA.
Selinger CI; Day CJ; Morrison NA
J Cell Biochem; 2005 Dec; 96(5):996-1002. PubMed ID: 16149069
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of human extracellular cysteine protease inhibitors by the secreted staphylococcal cysteine proteases, staphopain A and B.
Vincents B; Onnerfjord P; Gruca M; Potempa J; Abrahamson M
Biol Chem; 2007 Apr; 388(4):437-46. PubMed ID: 17391065
[TBL] [Abstract][Full Text] [Related]
39. Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium.
Hansen T; Petrow PK; Gaumann A; Keyszer GM; Eysel P; Eckardt A; Bräuer R; Kriegsmann J
J Rheumatol; 2000 Apr; 27(4):859-65. PubMed ID: 10782807
[TBL] [Abstract][Full Text] [Related]
40. Lysosomal cysteine and aspartic proteinases, acid phosphatase, and an endogenous cysteine proteinase inhibitor, cystatin-beta, in rat osteoclasts.
Ohsawa Y; Nitatori T; Higuchi S; Kominami E; Uchiyama Y
J Histochem Cytochem; 1993 Jul; 41(7):1075-83. PubMed ID: 8515049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
